Remove companies clearing-house-payments-co-llc
article thumbnail

Which VPN Providers Really Take Privacy Seriously in 2023?

TorrentFreak

Some VPN companies even own review sites. Vulnerabilities are always lurking around the corner and even with the most secure VPN, you still have to trust the VPN company with your data. Many of these questions relate to privacy and security, and the various companies answer them here in their own words. If not, why?

Privacy 137
article thumbnail

Biosimilars 2020 Year in Review

Fish & Richardson Trademark & Copyright Thoughts

As of the March 23, 2020 transition, however, all “biological product” applications previously approved under the FD&C Act were “deemed” approved under the PHS Act, and companies can now seek biosimilars and interchangeables of these biological products. As noted above, companies are already taking advantage of these new designations.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

A Look Back at India’s Top IP Developments of 2023

SpicyIP

[ This post has been co-authored with Jyotpreet Kaur, Tejaswini Kaushal, Praharsh Gour, and Swaraj Barooah ]. RDB and Co. GoDaddy LLC, Dynadot LLC to immediately lock and suspend the domain names [link] , [link] and [link]. Universal City Studios LLC and Ors v. a) Top 10 IP Judgements/Orders (Topicality/Impact) 1.

IP 124
article thumbnail

Recent Developments in Trade Secrets Damages

Fish & Richardson Trademark & Copyright Thoughts

Trade secrets can mean big business for companies that hold them, and damages awards for trade secret misappropriation can reach into the hundreds of millions of dollars. However, that presumption can be overcome if it is clear that the statute in question was intended to apply to conduct occurring outside the U.S.

article thumbnail

Biosimilars 2021 Year in Review

Fish & Richardson Trademark & Copyright Thoughts

Several other companies have also announced plans to pursue interchangeable status for biosimilar products. Consistent with this, as shown below in Table 2, numerous companies have publicly announced the submission and/or acceptance of new biosimilar BLAs. Stimufend ® (Fresenius Kabi). Neulasta ® (Amgen). pegfilgrastim.